{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:32:26Z","timestamp":1771263146313,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emergency Medicine Clinics of North America"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.emc.2010.01.011","type":"journal-article","created":{"date-parts":[[2010,4,22]],"date-time":"2010-04-22T04:36:21Z","timestamp":1271910981000},"page":"409-419","source":"Crossref","is-referenced-by-count":13,"title":["Metabolic and Hepatobiliary Side Effects of Antiretroviral Therapy (ART)"],"prefix":"10.1016","volume":"28","author":[{"given":"Daniel M.","family":"Lugassy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenna M.","family":"Farmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.emc.2010.01.011_bib1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/QAD.0b013e32802ef30c","article-title":"Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy","volume":"21","author":"Lima","year":"2007","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.emc.2010.01.011_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1570162053506964","article-title":"Inpatient care of the HIV infected patient in the highly active antiretroviral therapy (HAART) era","volume":"3","author":"Pulvirenti","year":"2005","journal-title":"Curr HIV Res"},{"issue":"8","key":"10.1016\/j.emc.2010.01.011_bib3","first-page":"390","article-title":"Changes in HIV-related hospitalizations during the HAART era in an inner-city hospital","volume":"17","author":"Pulvirenti","year":"2007","journal-title":"AIDS Read"},{"issue":"3","key":"10.1016\/j.emc.2010.01.011_bib4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.annemergmed.2008.01.324","article-title":"Care of the HIV-positive patient in the emergency department in the era of highly active antiretroviral therapy","volume":"52","author":"Venkat","year":"2008","journal-title":"Ann Emerg Med"},{"issue":"4","key":"10.1016\/j.emc.2010.01.011_bib5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/157016209788680633","article-title":"The changing face of HIV\/AIDS in treated patients","volume":"7","author":"Llibre","year":"2009","journal-title":"Curr HIV Res"},{"issue":"1","key":"10.1016\/j.emc.2010.01.011_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study","volume":"43","author":"Palella","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"10.1016\/j.emc.2010.01.011_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12245-008-0066-7","article-title":"Emergency department utilization by HIV-positive adults in the HAART era","volume":"1","author":"Venkat","year":"2008","journal-title":"Int J Emerg Med"},{"issue":"1","key":"10.1016\/j.emc.2010.01.011_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1545109708330906","article-title":"HIV-related liver disease: ARV drugs, coinfection, and other risk factors","volume":"8","author":"Puoti","year":"2009","journal-title":"J Int Assoc Physicians AIDS Care"},{"issue":"9","key":"10.1016\/j.emc.2010.01.011_bib9","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1089\/aid.2006.22.825","article-title":"Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients","volume":"22","author":"Nunez","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"10.1016\/j.emc.2010.01.011_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.1K522","article-title":"Abacavir hypersensitivity reaction: an update","volume":"42","author":"Hughes","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.emc.2010.01.011_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jama.292.2.243","article-title":"HIV infection, hepatitis C infection, and HAART: hard clinical choices","volume":"292","author":"Kottilil","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.emc.2010.01.011_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2165\/00002018-200528010-00004","article-title":"Hepatotoxicity of antiretrovirals: incidence, mechanisms and management","volume":"28","author":"Nunez","year":"2005","journal-title":"Drug Saf"},{"issue":"11","key":"10.1016\/j.emc.2010.01.011_bib13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa012035","article-title":"Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients","volume":"346","author":"Cote","year":"2002","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.emc.2010.01.011_bib14","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2165\/00003495-200363160-00003","article-title":"Atazanavir","volume":"63","author":"Goldsmith","year":"2003","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.emc.2010.01.011_bib15","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1086\/420932","article-title":"Atazanavir: new option for treatment of HIV infection","volume":"38","author":"Havlir","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.emc.2010.01.011_bib16","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2165\/00003495-199958060-00011","article-title":"Indinavir: a review of its use in the management of HIV infection","volume":"58","author":"Plosker","year":"1999","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.emc.2010.01.011_bib17","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jhep.2008.12.030","article-title":"Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy\u2013an extended haplotype of genetic variants increases risk in indinavir treatment","volume":"50","author":"Lankisch","year":"2009","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.emc.2010.01.011_bib18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/00002030-199710001-00008","article-title":"Hypersensitivity reactions during antiretroviral regimens with protease inhibitors","volume":"11","author":"Bonfanti","year":"1997","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.emc.2010.01.011_bib19","first-page":"55","article-title":"Clinical use of pharmacogenomic tests in 2009","volume":"30","author":"Sheffield","year":"2009","journal-title":"Clin Biochem Rev"},{"issue":"9","key":"10.1016\/j.emc.2010.01.011_bib20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1258\/0956462011923714","article-title":"The metabolic toxicities of antiretroviral therapy","volume":"12","author":"Herman","year":"2001","journal-title":"Int J STD AIDS"},{"issue":"3","key":"10.1016\/j.emc.2010.01.011_bib21","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7326\/0003-4819-133-3-200008010-00010","article-title":"Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases","volume":"133","author":"Miller","year":"2000","journal-title":"Ann Intern Med"},{"issue":"9184","key":"10.1016\/j.emc.2010.01.011_bib22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.emc.2010.01.011_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clnu.2004.03.009","article-title":"Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy","volume":"24","author":"Calza","year":"2005","journal-title":"Clin Nutr"},{"issue":"3","key":"10.1016\/j.emc.2010.01.011_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1310\/95VE-A6KJ-WRQ0-1F8Y","article-title":"Mild to moderate symptoms do not correlate with lactate levels in HIV-positive patients on nucleoside reverse transcriptase inhibitors","volume":"7","author":"Tan","year":"2006","journal-title":"HIV Clin Trials"},{"issue":"18","key":"10.1016\/j.emc.2010.01.011_bib25","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1097\/QAD.0b013e3282f08cdc","article-title":"Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy","volume":"21","author":"Lactic Acidosis International Study Group","year":"2007","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.emc.2010.01.011_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1258\/ijsa.2007.007076","article-title":"HIV infection and the pancreas: risk factors and potential management guidelines","volume":"19","author":"Manfredi","year":"2008","journal-title":"Int J STD AIDS"},{"issue":"5","key":"10.1016\/j.emc.2010.01.011_bib27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00002030-200103300-00011","article-title":"Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs","volume":"15","author":"Moore","year":"2001","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.emc.2010.01.011_bib28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0002-9343(96)00077-0","article-title":"Adverse events from drug therapy for human immunodeficiency virus disease","volume":"101","author":"Moore","year":"1996","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.emc.2010.01.011_bib29","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/clinids\/19.6.1076","article-title":"Rates and risk factors for adverse events associated with didanosine in the expanded access program","volume":"19","author":"Schindzielorz","year":"1994","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.emc.2010.01.011_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1136\/sti.79.4.340","article-title":"Lactic acidosis in HIV infected patients: a systematic review of published cases","volume":"79","author":"Arenas-Pinto","year":"2003","journal-title":"Sex Transm Infect"},{"issue":"2","key":"10.1016\/j.emc.2010.01.011_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/589294","article-title":"Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors","volume":"47","author":"Guaraldi","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.emc.2010.01.011_bib32","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"issue":"9079","key":"10.1016\/j.emc.2010.01.011_bib33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0140-6736(05)63513-1","article-title":"Protease inhibitor-associated hyperglycaemia","volume":"350","author":"Dube","year":"1997","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.emc.2010.01.011_bib34","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.emc.2010.01.011_bib35","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.emc.2010.01.011_bib36","article-title":"Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus","author":"Lumpkin","year":"1997"},{"issue":"5","key":"10.1016\/j.emc.2010.01.011_bib37","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200203290-00002","article-title":"Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study","volume":"16","author":"Noor","year":"2002","journal-title":"AIDS"},{"issue":"27","key":"10.1016\/j.emc.2010.01.011_bib38","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1074\/jbc.C000228200","article-title":"The mechanism of insulin resistance caused by HIV protease inhibitor therapy","volume":"275","author":"Murata","year":"2000","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.emc.2010.01.011_bib39","doi-asserted-by":"crossref","first-page":"E925","DOI":"10.1152\/ajpendo.90445.2008","article-title":"Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion","volume":"296","author":"Zhang","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.emc.2010.01.011_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1592\/phco.19.4.281.30937","article-title":"HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications","volume":"19","author":"Kaul","year":"1999","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.emc.2010.01.011_bib41","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0149-2918(04)90032-X","article-title":"Enfuvirtide: a fusion inhibitor for the treatment of HIV infection","volume":"26","author":"Fung","year":"2004","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.emc.2010.01.011_bib42","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1128\/AAC.44.4.821-826.2000","article-title":"Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function","volume":"44","author":"Veronese","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"21","key":"10.1016\/j.emc.2010.01.011_bib43","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-Moller","year":"2003","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.emc.2010.01.011_bib44","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1210\/jc.2008-1019","article-title":"Approach to the human immunodeficiency virus-infected patient with lipodystrophy","volume":"93","author":"Brown","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"8972","key":"10.1016\/j.emc.2010.01.011_bib45","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(95)92829-4","article-title":"Seizure associated with zidovudine","volume":"346","author":"D'Silva","year":"1995","journal-title":"Lancet"}],"container-title":["Emergency Medicine Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386271000012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386271000012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T13:51:00Z","timestamp":1544536260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386271000012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S073386271000012X"],"URL":"https:\/\/doi.org\/10.1016\/j.emc.2010.01.011","relation":{},"ISSN":["0733-8627"],"issn-type":[{"value":"0733-8627","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}